BS
Insider
Beth C Seidenberg
DirectorBeth C Seidenberg (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in KYTX. Across 1 priced purchase filing, the average 21-session return was +27.4% from execution and +44.4% from disclosure (delay-adjusted; derived). The largest single filing was $1000K of KYTX (133,333 sh × $7.50, as filed), executed Dec 18 2025.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+27.4%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+44.4%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells
Median delay
4d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$1000K
shares × price, as filed
Last traded
Dec 18 2025
Filed Dec 22 2025
Median ADV $64.6M across their filed names
Open performance→Volume by month
Buys $1000K
Sells $710K
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Not on file
1 filing
Sector per market data · by filing · past 12 months
Most traded names
KYTX
KYTX
KYTX · 1 buy · 0 sells
1 filing
VERA
Vera Therapeutics, Inc.
VERA · 0 buys · 1 sell
1 filing
Recent filings
KYTXPURCHASE
Kyverna Therapeutics, Inc.
View filing →
$1000K133,333 sh × $7.50
Exec Dec 18 2025
Filed Dec 22 2025 · 11:43 AM ET VERASALE Vera Therapeutics, Inc. View filing → $710K
14,798 sh × $48.01
Exec Oct 28 2024
Filed Oct 30 2024 · 5:30 PM ET VERASALE Vera Therapeutics, Inc. View filing → $585K
13,823 sh × $42.31
Exec Sep 19 2024
Filed Sep 20 2024 · 5:30 PM ET